InflaRx (NASDAQ:IFRX) Earns Buy Rating from HC Wainwright

InflaRx (NASDAQ:IFRX)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $8.00 price objective on the stock.

InflaRx Stock Performance

InflaRx stock opened at $1.21 on Friday. The firm has a market capitalization of $81.23 million, a P/E ratio of -1.12 and a beta of 1.98. InflaRx has a 1 year low of $1.17 and a 1 year high of $2.82. The business has a 50-day moving average of $2.16 and a 200-day moving average of $1.92.

Hedge Funds Weigh In On InflaRx

Institutional investors and hedge funds have recently modified their holdings of the business. Northern Trust Corp grew its position in shares of InflaRx by 1,933.1% in the 4th quarter. Northern Trust Corp now owns 666,845 shares of the company’s stock valued at $1,647,000 after purchasing an additional 634,045 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of InflaRx in the 4th quarter valued at approximately $55,000. Geode Capital Management LLC grew its position in shares of InflaRx by 32.8% in the 4th quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock valued at $119,000 after purchasing an additional 11,900 shares during the period. Two Sigma Securities LLC acquired a new position in shares of InflaRx in the 4th quarter valued at approximately $28,000. Finally, Raymond James Financial Inc. acquired a new position in shares of InflaRx in the 4th quarter valued at approximately $1,576,000. 42.39% of the stock is currently owned by institutional investors and hedge funds.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.